Literature DB >> 19208608

Prednisone, lupus activity, and permanent organ damage.

Mae Thamer1, Miguel A Hernán, Yi Zhang, Dennis Cotter, Michelle Petri.   

Abstract

OBJECTIVE: To estimate the effect of corticosteroids (prednisone dose) on permanent organ damage among persons with systemic lupus erythematosus (SLE).
METHODS: We identified 525 patients with incident SLE in the Hopkins Lupus Cohort. At each visit, clinical activity indices, laboratory data, and treatment were recorded. The study population was followed from the month after the first visit until June 29, 2006, or attainment of irreversible organ damage, death, loss to follow-up, or receipt of pulse methylprednisolone therapy. We estimated the effect of cumulative average dose of prednisone on organ damage using a marginal structural model to adjust for time-dependent confounding by indication due to SLE disease activity.
RESULTS: Compared with non-prednisone use, the hazard ratio of organ damage for prednisone was 1.16 (95% CI 0.54, 2.50) for cumulative average doses > 0-180 mg/month, 1.50 (95% CI 0.58, 3.88) for > 180-360 mg/month, 1.64 (95% CI 0.58, 4.69) for > 360-540 mg/month, and 2.51 (95% CI 0.87, 7.27) for > 540 mg/month. In contrast, standard Cox regression models estimated higher hazard ratios at all dose levels.
CONCLUSION: Our results suggest that low doses of prednisone do not result in a substantially increased risk of irreversible organ damage.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19208608      PMCID: PMC3624968          DOI: 10.3899/jrheum.080828

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  19 in total

1.  Hopkins Lupus Cohort. 1999 update.

Authors:  M Petri
Journal:  Rheum Dis Clin North Am       Date:  2000-05       Impact factor: 2.670

2.  Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men.

Authors:  M A Hernán; B Brumback; J M Robins
Journal:  Epidemiology       Date:  2000-09       Impact factor: 4.822

3.  Marginal structural models and causal inference in epidemiology.

Authors:  J M Robins; M A Hernán; B Brumback
Journal:  Epidemiology       Date:  2000-09       Impact factor: 4.822

Review 4.  Lupus in Baltimore: evidence-based 'clinical pearls' from the Hopkins Lupus Cohort.

Authors:  M Petri
Journal:  Lupus       Date:  2005       Impact factor: 2.911

5.  SLICC/ACR Damage Index in Afro-Caribbean patients with systemic lupus erythematosus: changes in and relationship to disease activity, corticosteroid therapy, and prognosis.

Authors:  J C Nossent
Journal:  J Rheumatol       Date:  1998-04       Impact factor: 4.666

6.  Measures of disease activity, damage, and health status: the Hopkins Lupus Cohort experience.

Authors:  M Petri; S G Barr; A Zonana-Nach; L Magder
Journal:  J Rheumatol       Date:  1999-02       Impact factor: 4.666

7.  Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians' Health Study.

Authors:  Nancy R Cook; Stephen R Cole; Charles H Hennekens
Journal:  Am J Epidemiol       Date:  2002-06-01       Impact factor: 4.897

8.  Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study.

Authors:  Hyon K Choi; Miguel A Hernán; John D Seeger; James M Robins; Frederick Wolfe
Journal:  Lancet       Date:  2002-04-06       Impact factor: 79.321

9.  Damage in systemic lupus erythematosus and its association with corticosteroids.

Authors:  A Zonana-Nacach; S G Barr; L S Magder; M Petri
Journal:  Arthritis Rheum       Date:  2000-08

Review 10.  The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.

Authors:  D Gladman; E Ginzler; C Goldsmith; P Fortin; M Liang; M Urowitz; P Bacon; S Bombardieri; J Hanly; E Hay; D Isenberg; J Jones; K Kalunian; P Maddison; O Nived; M Petri; M Richter; J Sanchez-Guerrero; M Snaith; G Sturfelt; D Symmons; A Zoma
Journal:  Arthritis Rheum       Date:  1996-03
View more
  49 in total

Review 1.  Glucocorticoids in 2015: New answers to old problems.

Authors:  Sarah A Jones; Eric F Morand
Journal:  Nat Rev Rheumatol       Date:  2015-12-24       Impact factor: 20.543

Review 2.  [Deescalation and glucocorticoid-free treatment in SLE].

Authors:  Rebecca Fischer-Betz; Matthias Schneider
Journal:  Z Rheumatol       Date:  2021-03-15       Impact factor: 1.372

Review 3.  Systemic lupus erythematosus: Diagnosis and clinical management.

Authors:  Andrea Fava; Michelle Petri
Journal:  J Autoimmun       Date:  2018-11-16       Impact factor: 7.094

Review 4.  Why targeted therapies are necessary for systemic lupus erythematosus.

Authors:  L Durcan; M Petri
Journal:  Lupus       Date:  2016-09       Impact factor: 2.911

Review 5.  Remission and withdrawal of therapy in lupus nephritis.

Authors:  Gabriella Moroni; Francesca Raffiotta; Claudio Ponticelli
Journal:  J Nephrol       Date:  2016-05-04       Impact factor: 3.902

6.  The risk benefit ratio of glucocorticoids in SLE: have things changed over the past 40 years?

Authors:  G Stojan; M Petri
Journal:  Curr Treatm Opt Rheumatol       Date:  2017-07-27

7.  Chronic high-dose glucocorticoid therapy triggers the development of chronic organ damage and worsens disease outcome in systemic lupus erythematosus.

Authors:  Tünde Tarr; Gábor Papp; Nikolett Nagy; Edina Cserép; Margit Zeher
Journal:  Clin Rheumatol       Date:  2016-11-26       Impact factor: 2.980

8.  Understanding systemic lupus erythematosus patients' desired outcomes and their perceptions of the risks and benefits of using corticosteroids.

Authors:  X Ng; S dosReis; R Beardsley; L Magder; C D Mullins; M Petri
Journal:  Lupus       Date:  2017-08-31       Impact factor: 2.911

Review 9.  Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus.

Authors:  Colin Thorbinson; Louise Oni; Eve Smith; Angela Midgley; Michael W Beresford
Journal:  Paediatr Drugs       Date:  2016-06       Impact factor: 3.022

10.  Presentation and outcome of paediatric membranous non-proliferative lupus nephritis.

Authors:  Boris Hugle; Earl D Silverman; Pascal N Tyrrell; Elizabeth A Harvey; Diane Hébert; Susanne M Benseler
Journal:  Pediatr Nephrol       Date:  2014-07-31       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.